Sars-Cov-2 Nvx-Cov2373 Vaccine, Recomb (Cvx 313) Dosage

Medically reviewed by Drugs.com. Last updated on Oct 4, 2023.

Usual Adult Dose for COVID-19

FOR INVESTIGATIONAL USE ONLY

Previously vaccinated with any coronavirus disease 2019 (COVID-19) vaccine: 0.5 mL IM once, administered at least 2 months after the last dose of COVID-19 vaccine
No prior history of vaccination: 0.5 mL IM for 2 doses, administered 3 weeks apart

Comments:

• This drug is not approved by the US FDA to prevent COVID-19. The US FDA has issued an Emergency Use Authorization (EUA) for the use of this drug to prevent COVID-19.
• An additional dose administered at least 2 months following the last dose of this vaccine may be considered for patients who are severely immunocompromised (based on the healthcare provider's discretion).
• No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.

Use: For active immunization to prevent COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Usual Pediatric Dose for COVID-19

FOR INVESTIGATIONAL USE ONLY

12 years and older:

• Previously vaccinated with any COVID-19 vaccine: 0.5 mL IM once, administered at least 2 months after the last dose of COVID-19 vaccine
• No prior history of vaccination: 0.5 mL IM for 2 doses, administered 3 weeks apart

Comments:

• This drug is not approved by the US FDA to prevent COVID-19. The US FDA has issued an EUA for the use of this drug to prevent COVID-19.
• An additional dose administered at least 2 months following the last dose of this vaccine may be considered for patients who are severely immunocompromised (based on the healthcare provider's discretion).
• No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.

Use: For active immunization to prevent COVID-19 due to SARS-CoV-2

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Patients with a severe allergic reaction (e.g., anaphylaxis) to any of the ingredients
• Severe allergic reaction following a previous dose of this vaccine

Safety and efficacy have not been established in patients younger than 12 years; this drug is not recommended for use in these patients.

Dialysis

Data not available

Other Comments

Administration advice:

• For IM administration only.
• Do not dilute; multidose vials contain five-0.5 mL doses of vaccine.

Storage requirements:

• Prior to first puncture of vial, store at 2C to 8C (36F to 46F) and protect from light; do not freeze.
• After first puncture of vial AND once the first dose is withdrawn, store between 2C to 25C (36F to 77F) for up to 12 hours; discard the open vial if not used within the time frame.

Reconstitution/preparation techniques:

• Once opened, record the date and time of first use on the vaccine vial label.

General:

• This vaccine is preservative free.

Patient advice:

• Read the Fact Sheet for Recipients and Caregivers.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer